Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CMMB Stock Forecast 2025-2026
$2.66
Current Price
$28.70M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CMMB Price Targets
+952.6%
To High Target of $28.00
+896.2%
To Median Target of $26.50
+839.8%
To Low Target of $25.00
CMMB Price Momentum
+0.8%
1 Week Change
-21.3%
1 Month Change
-60.3%
1 Year Change
-63.3%
Year-to-Date Change
-73.0%
From 52W High of $9.84
+11.3%
From 52W Low of $2.39
📊 TOP ANALYST CALLS
Did CMMB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Chemomab is one of their latest high-conviction picks.
Latest CMMB Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CMMB has a bullish consensus with a median price target of $26.50 (ranging from $25.00 to $28.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.66, the median forecast implies a 896.2% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jeff Jones at Oppenheimer, suggesting a 839.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMMB Analyst Ratings
2
Buy
0
Hold
0
Sell
CMMB Price Target Range
Low
$25.00
Average
$26.50
High
$28.00
Current: $2.66
Latest CMMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMMB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $25.00 |
| May 16, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $10.00 |
| Feb 20, 2025 | Maxim Group | Michael Okunewitch | Buy | Maintains | $7.00 |
| Nov 15, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $11.00 |
| May 13, 2024 | Maxim Group | Michael Okunewitch | Buy | Initiates | $4.00 |
| May 6, 2024 | Oppenheimer | Jeff Jones | Outperform | Upgrade | $6.00 |
| Mar 8, 2024 | Oppenheimer | Jeff Jones | Perform | Maintains | $N/A |
| Dec 19, 2023 | Roth MKM | Dylan Dupuis | Buy | Reinstates | $7.00 |
| Oct 6, 2023 | Roth MKM | Dylan Dupuis | Buy | Initiates | $7.00 |
| Jun 7, 2023 | Oppenheimer | Jeff Jones | Perform | Downgrade | $N/A |
| Apr 18, 2023 | Oppenheimer | Jeff Jones | Outperform | Maintains | $7.00 |
| Mar 10, 2022 | Oppenheimer | Jeff Jones | Outperform | Maintains | $20.00 |
| Dec 7, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| May 26, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| May 7, 2021 | Oppenheimer | Outperform | Initiates | $N/A |
Chemomab Therapeutics Ltd. (CMMB) Competitors
The following stocks are similar to Chemomab based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Chemomab Therapeutics Ltd. (CMMB) Financial Data
Chemomab Therapeutics Ltd. has a market capitalization of $28.70M with a P/E ratio of -0.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -120.2%.
Valuation Metrics
Market Cap
$28.70M
Enterprise Value
$1.10B
P/E Ratio
-0.8x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.9%
Current Ratio
7.4x
Debt/Equity
0.0x
ROE
-120.2%
ROA
-61.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Chemomab Therapeutics Ltd. (CMMB) Business Model
About Chemomab Therapeutics Ltd.
What They Do
Develops treatments for inflammation and fibrosis.
Business Model
The company focuses on discovering and developing innovative biopharmaceuticals that target diseases characterized by inflammation and fibrosis. Chemomab generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its therapeutic products as they advance through clinical trials and receive regulatory approval.
Additional Information
Headquartered in Israel, Chemomab Therapeutics is positioned in a region recognized for its technological innovation, which enhances its ability to translate scientific discoveries into clinical applications. The company targets serious health conditions like liver fibrosis and systemic sclerosis, addressing significant unmet medical needs in the healthcare market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Dr. Adi Mor George Ph.D.
Country
Israel
IPO Year
2019
Website
www.chemomab.comChemomab Therapeutics Ltd. (CMMB) Latest News & Analysis
Latest News
Quick Summary
Chemomab will present three significant findings at AASLD The Liver Meeting® 2025, showcasing clinical data from the Phase 2 trial of nebokitug in primary sclerosing cholangitis (PSC).
Why It Matters
Chemomab's positive presentations at a major conference highlight promising clinical data for nebokitug, potentially boosting investor confidence and influencing stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MQ, GES, TRV, CMMB, and PARR are now rated as Zacks Rank #1 (Strong Buy) as of October 23, 2025.
Why It Matters
Strong Buy ratings from Zacks indicate potential for significant stock price appreciation, attracting investor interest and possibly driving up demand for MQ, GES, TRV, CMMB, and PARR.
Source: Zacks Investment Research
Market Sentiment:
Positive
Best Momentum Stocks to Buy for Oct. 23
22 days ago
Quick Summary
PARR, CMMB, and GES have been rated as Zacks Rank #1 (Strong Buy) momentum stocks as of October 23, 2025.
Why It Matters
Zacks Rank #1 indicates strong potential for PARR, CMMB, and GES, suggesting likely price appreciation and positive momentum, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
2 months ago
Quick Summary
Chemomab Therapeutics (Nasdaq: CMMB) announced CEO Dr. Adi Mor will present at the H.C. conference, highlighting its focus on therapeutics for fibro-inflammatory diseases.
Why It Matters
Chemomab's CEO presentation could signal upcoming developments or insights, potentially influencing stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
3 months ago
Quick Summary
Chemomab Therapeutics is advancing its Phase 3 program for Nebokitug, with promising Phase 2 data presented at major meetings. They have cash to fund operations through Q2 2026 and plan an ADS ratio adjustment.
Why It Matters
Advancements in Nebokitug's Phase 3 preparations and strong Phase 2 data signal potential for future revenue, while a solid cash runway through mid-2026 supports ongoing operations and development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Chemomab Therapeutics presented positive Phase 2 SPRING trial data for nebokitug, a treatment for primary sclerosing cholangitis (PSC), supporting its advancement to Phase 3 trials.
Why It Matters
Positive SPRING trial data for nebokitug suggests strong market potential in treating PSC, indicating future revenue growth for Chemomab Therapeutics and enhancing investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CMMB Stock
What is Chemomab Therapeutics Ltd.'s (CMMB) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Chemomab Therapeutics Ltd. (CMMB) has a median price target of $26.50. The highest price target is $28.00 and the lowest is $25.00.
Is CMMB stock a good investment in 2026?
According to current analyst ratings, CMMB has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.66. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMMB stock?
Wall Street analysts predict CMMB stock could reach $26.50 in the next 12 months. This represents a 896.2% increase from the current price of $2.66. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Chemomab Therapeutics Ltd.'s business model?
The company focuses on discovering and developing innovative biopharmaceuticals that target diseases characterized by inflammation and fibrosis. Chemomab generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its therapeutic products as they advance through clinical trials and receive regulatory approval.
What is the highest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The highest price target for CMMB is $28.00 from at , which represents a 952.6% increase from the current price of $2.66.
What is the lowest forecasted price for CMMB Chemomab Therapeutics Ltd.?
The lowest price target for CMMB is $25.00 from Jeff Jones at Oppenheimer, which represents a 839.8% increase from the current price of $2.66.
What is the overall CMMB consensus from analysts for Chemomab Therapeutics Ltd.?
The overall analyst consensus for CMMB is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $26.50.
How accurate are CMMB stock price projections?
Stock price projections, including those for Chemomab Therapeutics Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 2:33 AM UTC